Has fotantinib/fotantinib been successfully copied in India?

Fostamatinib, an oral splenic tyrosine kinase (SYK) inhibitor, is indicated for the treatment of chronic immune thrombocytopenia (ITP) in adults, particularly in patients who have failed to respond to previous treatments, such as glucocorticoids, immunoglobulins, or splenectomy. Immune thrombocytopenia is a rare autoimmune disease in which the patient's immune system mistakenly attacks the patient's own platelets, resulting in a low number of platelets, leading to risks such as bleeding and bruising.

Fotantinib reduces the immune system's destruction of platelets by inhibiting theSYK signaling pathway, thereby helping to increase platelet levels and alleviate clinical symptoms. The drug was first approved in the United States in 2018, and was subsequently gradually launched in Europe and other regions. It was officially sold by the original drug company in Germany and other countries under the trade name TAVALISSE.

Up to now, fotantinib has not been successfully copied in India, nor does it appear in the list of generic drugs approved by the Drug Controller General of India. Although India is a major producer and exporter of generic drugs in the world, many innovative drugs will be developed as generics by local companies before and after their patents expire. However, because fotantinib is a newer targeted drug, its global use is relatively limited, and the original patent is still valid. These factors have made the progress of imitation in India not yet publicly reported.

In addition, fotantinib has not been officially approved for marketing in India, which also limits the local registration and commercialization process of generic drugs. In other words, if patients currently need fotantinib in India or other countries, they can only obtain it through original drug channels in countries such as Germany.

To sum up, there is currently no generic version of fotantinib that has been marketed overseas, and it has not yet been successfully imitated in India. It is still in the stage where the original drug dominates the market.

Reference materials:https://go.drugbank.com/drugs/DB12010